Announced
Synopsis
China Grand Pharmaceutical and CDH Genetech Limited, two healthcare companies, agreed to acquire Sirtex Medical, a global life sciences and life technology company, which develop and provide effective cancer treatment products, for $1.3bn. “CDH recognizes Australia’s leadership in medical research and its world-class regulatory system. In particular, CDH sees significant potential to introduce Sirtex’s liver cancer treatment product into China,” CHD Genetech.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.